CAESAREA, Israel - IceCure Medical Ltd. , developer of the ProSense System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal,.
IceCure Medical Ltd. has announced that the Food and Drug Administration (FDA) has granted its appeal and reopened its De Novo Classification Request for Marketing Authorization of its ProSense cryoablation technology for early-stage breast cancer.
By Colin Kellaher IceCure Medical shares rallied Monday after the medical-device company said an independent study concluded that cryoablation could be an.